TransCode Therapeutics Files Definitive Proxy Statement
Ticker: RNAZ · Form: DEF 14A · Filed: Apr 11, 2025 · CIK: 1829635
Sentiment: neutral
Topics: proxy-statement, annual-meeting, governance
TL;DR
TransCode Proxy Filed: Vote on directors & auditors. Standard annual meeting stuff.
AI Summary
TransCode Therapeutics, Inc. filed its definitive proxy statement on April 11, 2025, for its annual meeting of stockholders. The filing outlines the proposals to be voted on, including the election of directors and the ratification of the appointment of its independent registered public accounting firm. The company is seeking shareholder approval for these matters to continue its operations and governance.
Why It Matters
This filing provides shareholders with crucial information about the company's leadership and financial oversight, enabling them to make informed voting decisions.
Risk Assessment
Risk Level: low — This is a routine annual proxy filing, not indicating any immediate financial distress or significant new risks.
Key Players & Entities
- TransCode Therapeutics, Inc. (company) — Registrant
- 0001104659-25-034266 (filing_id) — Accession Number
- 20250411 (date) — Filing Date
- 20250421 (date) — Period of Report
FAQ
What is the purpose of this DEF 14A filing?
The purpose of this DEF 14A filing is to provide TransCode Therapeutics, Inc. shareholders with the definitive proxy statement for their annual meeting, outlining proposals for voting, including the election of directors and ratification of the independent auditor.
When was this filing submitted to the SEC?
This filing was submitted to the SEC on April 11, 2025.
What is the fiscal year end for TransCode Therapeutics, Inc.?
The fiscal year end for TransCode Therapeutics, Inc. is December 31.
What is the company's Standard Industrial Classification (SIC) code?
The company's Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
What is the company's business address?
The company's business address is 6 Liberty Square, #2382, Boston, MA 02109.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 11, 2025 regarding Transcode Therapeutics, Inc. (RNAZ).